The Follicular Lymphoma Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Follicular Lymphoma Treatment Market:
https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report
According to The Business Research Company’s Follicular Lymphoma Treatment Global Market Report 2024, The follicular lymphoma treatment market size has grown strongly in recent years. It will grow from $2.83 billion in 2023 to $3.09 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increased incidence of follicular lymphoma, advancements in cancer diagnostics, expanding aging population, clinical research and drug development, collaborations in oncology research.
The follicular lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to personalized medicine approaches, immunotherapy advancements, expanded access to innovative therapies, focus on quality of life, global oncology collaboration initiatives. Major trends in the forecast period include clinical trials and research initiatives, exploration of epigenetic modifiers, enhancements in radioimmunotherapy, application of artificial intelligence (ai), global collaboration for access to therapies.
The rising prevalence of follicular lymphoma is expected to propel the growth of the follicular lymphoma treatment market moving forward. The prevalence of follicular lymphoma refers to the total number or proportion of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This shift has resulted from the rise in the aging population, genetic predisposition, improved diagnostic techniques, and increased awareness and screening. Follicular lymphoma treatment helps reduce the prevalence of follicular lymphoma by addressing the disease at various stages and aids in disease treatment and progression. The rise in the incidence of follicular lymphoma is boosting the growth of the follicular lymphoma treatment market. For instance, in January 2023, according to the American Cancer Society, a US-based Voluntary organization, non-Hodgkin lymphoma, a type of indolent follicular lymphoma, is the most frequent cancer in the US, accounting for around 4% of all cancers. The American Cancer Society projects that NHL will be diagnosed in approximately 80,550 persons (44,880 men and 35,670 women). This includes both adults and children. Therefore, the rising prevalence of follicular lymphoma is driving the growth of the follicular lymphoma treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp
The follicular lymphoma treatment market covered in this report is segmented –
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Other Treatments
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users
Technological advancements in the diagnosis and treatment of follicular lymphoma are a key trend-gaining opportunity in the follicular lymphoma treatment market. Companies operating in the follicular lymphoma treatment market are adopting advanced diagnoses and treatments for follicular lymphoma to sustain their position in the market. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody is a new class of fixed-duration cancer treatment immunotherapy, and it is a readily available and off-the-shelf treatment options patients are not needed to wait to receive this immunotherapy treatment. The FDA approval is based on positive results from the Lunsumio Phase II GO29781 research in persons with extensively pretreated FL, particularly those at high risk of illness progression or unresponsive to prior treatments.
The follicular lymphoma treatment market report table of contents includes:
1. Executive Summary
2. Follicular Lymphoma Treatment Market Characteristics
3. Follicular Lymphoma Treatment Market Trends And Strategies
4. Follicular Lymphoma Treatment Market – Macro Economic Scenario
5. Global Follicular Lymphoma Treatment Market Size and Growth
….
31. Global Follicular Lymphoma Treatment Market Competitive Benchmarking
32. Global Follicular Lymphoma Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Follicular Lymphoma Treatment Market
34. Follicular Lymphoma Treatment Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
